168 related articles for article (PubMed ID: 23719766)
1. S-1 (Teysuno®): a review of its use in advanced gastric cancer in non-Asian populations.
Sanford M
Drugs; 2013 Jun; 73(8):845-55. PubMed ID: 23719766
[TBL] [Abstract][Full Text] [Related]
2. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
3. The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for human use (CHMP).
Matt P; van Zwieten-Boot B; Calvo Rojas G; Ter Hofstede H; Garcia-Carbonero R; Camarero J; Abadie E; Pignatti F
Oncologist; 2011; 16(10):1451-7. PubMed ID: 21963999
[TBL] [Abstract][Full Text] [Related]
4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Boku N; Yamamoto S; Fukuda H; Shirao K; Doi T; Sawaki A; Koizumi W; Saito H; Yamaguchi K; Takiuchi H; Nasu J; Ohtsu A;
Lancet Oncol; 2009 Nov; 10(11):1063-9. PubMed ID: 19818685
[TBL] [Abstract][Full Text] [Related]
5. New Perspectives in the Treatment of Advanced Gastric Cancer: S-1 as a Novel Oral 5-FU Therapy in Combination with Cisplatin.
Mahlberg R; Lorenzen S; Thuss-Patience P; Heinemann V; Pfeiffer P; Möhler M
Chemotherapy; 2017; 62(1):62-70. PubMed ID: 27643822
[TBL] [Abstract][Full Text] [Related]
6. S-1 for the treatment of gastrointestinal cancer.
Satoh T; Sakata Y
Expert Opin Pharmacother; 2012 Sep; 13(13):1943-59. PubMed ID: 22860709
[TBL] [Abstract][Full Text] [Related]
7. Tegafur + gimeracil + oteracil. Just another fluorouracil precursor.
Prescrire Int; 2013 May; 22(138):122. PubMed ID: 23819172
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).
Ohtsu A; Shimada Y; Shirao K; Boku N; Hyodo I; Saito H; Yamamichi N; Miyata Y; Ikeda N; Yamamoto S; Fukuda H; Yoshida S;
J Clin Oncol; 2003 Jan; 21(1):54-9. PubMed ID: 12506170
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer.
Lee SJ; Cho SH; Yoon JY; Hwang JE; Bae WK; Shim HJ; Chung IJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):159-66. PubMed ID: 19479256
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of cetuximab plus S-1/cisplatin therapy in Japanese patients with advanced gastric cancer.
Yamaguchi K; Fuse N; Komatsu Y; Fujii H; Hironaka S; Omuro Y; Muro K; Yasui H; Ueda S; Nishina T; Watanabe M; Ohtsu A
Jpn J Clin Oncol; 2021 May; 51(6):879-885. PubMed ID: 33561262
[TBL] [Abstract][Full Text] [Related]
11. Treatment of gastric cancer in Asia: the missing link.
Nishida T
Lancet Oncol; 2009 Nov; 10(11):1027-8. PubMed ID: 19880057
[No Abstract] [Full Text] [Related]
12. S-1 in gastric cancer: a comprehensive review.
Maehara Y
Gastric Cancer; 2003; 6 Suppl 1():2-8. PubMed ID: 12775012
[TBL] [Abstract][Full Text] [Related]
13. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer.
Baba H; Yamamoto M; Endo K; Ikeda Y; Toh Y; Kohnoe S; Okamura T
Gastric Cancer; 2003; 6 Suppl 1():45-9. PubMed ID: 12775020
[TBL] [Abstract][Full Text] [Related]
15. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
Ajani JA; Buyse M; Lichinitser M; Gorbunova V; Bodoky G; Douillard JY; Cascinu S; Heinemann V; Zaucha R; Carrato A; Ferry D; Moiseyenko V
Eur J Cancer; 2013 Nov; 49(17):3616-24. PubMed ID: 23899532
[TBL] [Abstract][Full Text] [Related]
16. Can S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysis.
Chen XD; He FQ; Chen M; Tang LC; Tang XL
Medicine (Baltimore); 2016 Jun; 95(24):e3916. PubMed ID: 27310997
[TBL] [Abstract][Full Text] [Related]
17. [S-1 for gastric cancer-S-1 monotherapy and its progress].
Shitara K; Sakata Y; Kudou T; Munakata M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
[TBL] [Abstract][Full Text] [Related]
18. S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
Lv F; Liu X; Wang B; Guo H; Li J; Shen L; Jin M
Int J Clin Exp Pathol; 2014; 7(6):3293-8. PubMed ID: 25031751
[TBL] [Abstract][Full Text] [Related]
19. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial.
Kang YK; Chin K; Chung HC; Kadowaki S; Oh SC; Nakayama N; Lee KW; Hara H; Chung IJ; Tsuda M; Park SH; Hosaka H; Hironaka S; Miyata Y; Ryu MH; Baba H; Hyodo I; Bang YJ; Boku N
Lancet Oncol; 2020 Aug; 21(8):1045-1056. PubMed ID: 32682457
[TBL] [Abstract][Full Text] [Related]
20. Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study.
Qiao G; Wang X; Zhou L; Zhou X; Song Y; Wang S; Zhao L; Morse MA; Hobeika A; Song J; Yi X; Xia X; Ren J; Lyerly HK
Clin Cancer Res; 2019 Mar; 25(5):1494-1504. PubMed ID: 30514775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
